Catalyst Capital Advisors LLC Makes New Investment in The Clorox Company (NYSE:CLX)

Catalyst Capital Advisors LLC purchased a new stake in shares of The Clorox Company (NYSE:CLX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 329 shares of the company’s stock, valued at approximately $54,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of CLX. Innealta Capital LLC purchased a new stake in Clorox during the second quarter valued at $30,000. Trifecta Capital Advisors LLC grew its stake in shares of Clorox by 139.8% during the 2nd quarter. Trifecta Capital Advisors LLC now owns 223 shares of the company’s stock valued at $30,000 after purchasing an additional 130 shares during the period. First Foundation Advisors purchased a new stake in shares of Clorox during the 1st quarter valued at about $31,000. Family Firm Inc. bought a new position in shares of Clorox in the 2nd quarter worth approximately $31,000. Finally, Quarry LP boosted its holdings in shares of Clorox by 99.1% in the second quarter. Quarry LP now owns 229 shares of the company’s stock worth $31,000 after buying an additional 114 shares during the last quarter. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

Clorox Stock Performance

Shares of NYSE CLX opened at $162.70 on Thursday. The company has a market cap of $20.14 billion, a P/E ratio of 56.69, a P/E/G ratio of 3.11 and a beta of 0.41. The Clorox Company has a 52-week low of $127.60 and a 52-week high of $169.09. The company has a debt-to-equity ratio of 11.08, a quick ratio of 0.62 and a current ratio of 1.00. The firm’s fifty day moving average is $161.89 and its two-hundred day moving average is $146.58.

Clorox (NYSE:CLX) last posted its earnings results on Wednesday, October 30th. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.50. The company had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.64 billion. Clorox had a return on equity of 316.08% and a net margin of 4.78%. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.49 earnings per share. As a group, analysts anticipate that The Clorox Company will post 6.81 EPS for the current fiscal year.

Clorox Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 7th. Investors of record on Wednesday, October 23rd will be given a $1.22 dividend. This represents a $4.88 annualized dividend and a yield of 3.00%. The ex-dividend date is Wednesday, October 23rd. Clorox’s dividend payout ratio is presently 170.03%.

Insider Activity at Clorox

In other news, EVP Angela C. Hilt sold 1,733 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $165.52, for a total value of $286,846.16. Following the sale, the executive vice president now directly owns 13,471 shares in the company, valued at $2,229,719.92. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.57% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Deutsche Bank Aktiengesellschaft upped their target price on shares of Clorox from $144.00 to $151.00 and gave the company a “hold” rating in a report on Friday, August 2nd. Jefferies Financial Group upgraded Clorox from a “hold” rating to a “buy” rating and lifted their target price for the company from $174.00 to $187.00 in a research report on Tuesday, October 1st. TD Cowen upgraded Clorox from a “sell” rating to a “hold” rating and upped their price target for the stock from $155.00 to $170.00 in a research report on Wednesday. Barclays raised their price objective on Clorox from $137.00 to $139.00 and gave the stock an “underweight” rating in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. boosted their price objective on Clorox from $148.00 to $174.00 and gave the company a “neutral” rating in a research note on Friday, October 11th. Five research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $155.00.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.